Raf Crabbé
16 Papers
445 Citations
Raf Crabbé is an academic researcher. The author has contributed to research in topics: Cyclophilin & Alisporivir. The author has an hindex of 8, co-authored 12 publications.
Chat about Author
Papers
The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naive hepatitis C patients.
Robert Flisiak,Saya V. Feinman,Maciej Jabłkowski,Andrzej Horban,Wiesław Kryczka,Małgorzata Pawłowska,Jenny Heathcote,Giuseppe Mazzella,Carmen Vandelli,Valerie Nicolas-Metral,Pierre Grosgurin,J. S. Liz,Pietro Scalfaro,Hervé Porchet,Raf Crabbé +14 more
TL;DR: Debio 025 has a potent activity and an additive effect on HCV RNA reduction in genotype 1 and 4 patients at 600 and 1,000 mg/day when combined with PEG IFN‐α2a.
266
An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C.
Raf Crabbé,Grégoire Vuagniaux,Jean-Maurice Dumont,Valerie Nicolas-Metral,Judith Marfurt,Laura Novaroli +5 more
TL;DR: Debio 025 is a potent anti-HCV drug, with a novel mechanism of action and an efficacy profile that makes it an attractive candidate for combination with current and future HCV treatments.
48
Cyclophilin inhibitors in hepatitis C viral infection.
TL;DR: By interfering at the level of host–viral interaction, Cyp inhibition may open the way for a novel approach to anti-HCV treatment that could be complementary, not only to interferon-based treatment, but also to future treatments that directly target HCV replication enzymes such as protease and polymerase inhibitors.
47
143 efficacy and safety of increasing doses of the cyclophilin inhibitor debio 025 in combination with pegylated interferon alpha-2a in treatment naive chronic hcv patients
Robert Flisiak,Saya V. Feinman,Maciej Jabłkowski,Andrzej Horban,Wiesław Kryczka,Waldemar Halota,Jenny Heathcote,Giuseppe Mazzella,Carmen Vandelli,J. S. Liz,Raf Crabbé,Pietro Scalfaro,Hervé Porchet +12 more
27
95 efficacy and safety of the cyclophilin inhibitor debio 025 in combination with pegylated interferon alpha-2a and ribavirin in previously null-responder genotype 1 hcv patients
David R. Nelson,Reem Ghalib,M.S. Sulkowski,Eugene R. Schiff,Vinod K. Rustgi,Paul J. Pockros,C. Wang,G. Decosterd Kerhuel,P. Grosgurin,Hervé Porchet,Raf Crabbé +10 more
TL;DR: This research presents a novel and scalable approach called “Decosterd Kerhuel’s method,” which combines cell reprograming and “situational awareness” that aims to improve the quality of life of patients undergoing liver transplantation.
27